

ERRATUM

Open Access



# Erratum: Timp1 interacts with beta-1 integrin and CD63 along melanoma genesis and confers anoikis resistance by activating PI3-K signaling pathway independently of Akt phosphorylation

Mariana Toricelli<sup>1</sup>, Fabiana H. M. Melo<sup>1,2</sup>, Giovani B. Peres<sup>3</sup>, Débora C. P. Silva<sup>4</sup> and Miriam G. Jasiulionis<sup>1\*</sup>

## Erratum

After publication of this study [1], we found out that we unfortunately sent two figures in duplicate. They are Fig. 4b NT and Fig. 6c NT [1]. It is important to emphasize that the results shown in the graphs are correct since they represent the mean of three independent biological assays, each of them made in technical triplicates. The photographs are only representative figures of three biological assays.

## Competing interests

The authors declare that they have no competing interests.

## Authors' contributions

Conceived and designed the experiments: MT, FHMM, MGJ. Performed the experiments: MT, GBP. Analyzed the data: MT, FHMM, GBP, MGJ. Contributed reagents/materials/analysis: MT, FHMM, GBP, DCPS, MGJ. Wrote the paper: MT, FHMM, MGJ. All authors read and approved the final manuscript.

## Author details

<sup>1</sup>Pharmacology Department, Universidade Federal de São Paulo, São Paulo, Brazil. <sup>2</sup>Microbiology, Immunology and Parasitology Department, Universidade Federal de São Paulo, São Paulo, Brazil. <sup>3</sup>Biochemistry Department, Universidade Federal de São Paulo, São Paulo, Brazil. <sup>4</sup>Ludwig Institute for Cancer Research, São Paulo, Brazil.

Published online: 22 August 2015

## Reference

1. Mariana T, Fabiana HM M, Peres GB, Débora CP S, Jasiulionis MG. Timp1 interacts with beta-1 integrin and CD63 along melanoma genesis and confers anoikis resistance by activating PI3-K signaling pathway independently of Akt phosphorylation. *Molecular Cancer*. 2013;12:22.

\* Correspondence: [mjasiulionis@gmail.com](mailto:mjasiulionis@gmail.com)


<sup>1</sup>Pharmacology Department, Universidade Federal de São Paulo, São Paulo, Brazil

Submit your next manuscript to BioMed Central and take full advantage of:


- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)





**Fig. 4** PI3-K signaling pathway is involved in *anoikis* resistance phenotype conferred by Timp1. The MaGFP and MaT1S cell lines were treated overnight with PI3-K inhibitors, Wortmannin (a) or LY294002 (b), and their clonogenic capability was evaluated. c Melan-a melanocytes stably transfected with GFP (control transfection, MaGFP) and Timp1 (MaT1S) were maintained in suspension for 1, 3, 5 and 24 hours. The Akt activation was assessed by Western blotting. \*p < 0.05, \*\*p < 0.01, \*\*\*\*p < 0.0001



**Fig. 6** PI3-K inhibition renders melanoma cells *anoikis* sensitive. The 4C11- and 4C11+ melanoma cell lines were maintained in suspension for 96 hours in the presence of Wortmannin (a and b, respectively) or LY294002 (c and d, respectively). After 96 hours, suspended cells were plated and after 5 days clonogenic capacity was analyzed. 4C11-: non-metastatic melanoma cells; 4C11+: metastatic melanoma cells; NT: non-treated; Wn: Wortmannin; LY: LY294002. \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001